Table 2 Model inputs.
Probabilities | Mean | SD | Distribution |
|---|---|---|---|
Remission with DBS in year 1 | 0.242 | 0.17 | Beta |
Remission with DBS in year 2 | 0.030 | 0.08 | Beta |
Remission with DBS in year 3 | 0.047 | 0.14 | Beta |
Remission with DBS in year 4 | 0.010 | 0.005 | Beta |
Remission with DBS in year 5 | 0.010 | 0.005 | Beta |
Remission with TAU | 0.010 | 0.005 | Beta |
Complications after DBS | 0.158 | Uniform | |
IPG revision/replacement | 0.209 | Uniform | |
Lead revision/replacement | 0.349 | Uniform | |
Short hospitalization (3–7 days) | 0.442 | Uniform | |
Utilities (per QALY) | |||
Remission | 0.840 | 0.15 | Normal |
Non-remission | 0.540 | 0.25 | Normal |
Complications | 0.026 | 0.02 | Normal |
Costs ($) | |||
DBS-pc (5 years) | 120,566.85 | 817.66 | Gamma |
DBS-rc (5 years) | 29,524.05 | 817.66 | Gamma |
TAU (healthcare sector perspective) | 16,032.51 | 7832.53 | Gamma |
TAU (societal perspective) | 38,575.86 | 5722.14 | Gamma |
Pharmacotherapy alone | 1576.00 | 1174.00 | Gamma |
Short hospitalization | 13,035.00 | 5214.00 | Gamma |
IPG revision/replacement | 30,347.60 | Uniform | |
Lead revision/replacement | 27,066.84 | Uniform | |
